Compare Brunswick Corporation (BC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Mesoblast Limited — how do they compare? Brunswick Corporation trades at $78.83 (market cap $5.28B), while Mesoblast Limited trades at $16.9 (market cap $2.21B). The key difference: Brunswick Corporation is far larger — about 2.4× Mesoblast Limited's market cap, and Brunswick Corporation pays a 2.16% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BC | MESO | |
|---|---|---|
Market Cap | $5.28B | $2.21B |
Sector | Consumer Cyclical | Technology |
52-Week High | $89.22 | $20.96 |
52-Week Low | $58.75 | $12.88 |
Enterprise Value | $7.28B | $2.21B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BC trades at $80.43, down 1.37% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $1.56 versus $1.19 estimated, and the company maintains a dividend payout. Despite negative net income margins and ROE, revenue trends show stabilization, and cash flow from operations remains positive at $562.10M for 2025.
The outlook is cautiously optimistic, driven by earnings beats and a consensus price target of $85.33, but risks include persistent unprofitability and high debt levels. Investors may find opportunity in the bullish technical setup and institutional buying, though margin pressures and competitive challenges warrant close monitoring.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
